Where is CSBio located?

CSBio is headquartered in Menlo Park, United States. It is registered at Menlo Park, California.

How many employees does CSBio have?

As of Dec 31, 2022, the latest employee count at CSBio is 59.

Is CSBio a funded company?

CSBio is a funded company, having raised a total of $***** in its 1st and only funding round.

Where does CSBio rank among its competitors?

CSBio ranks 18th amongst 64 active competitors, of which 8 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Enzene, which secured $50M in Jan, 2023.

Who are the top competitors of CSBio?

CSBio's top competitors include Enzene, Shaanxi Micot Technology and PolyPeptide. Among them, Enzene secured the most recent funding round in January, 2023.

CSBio - 2026 Company Profile, Competitors & Financials

CSBio is an unfunded company based in Menlo Park (United States), founded in 1993. It operates as a Peptide synthesizers, DNA synthesizers, and peptide manufacturing for the pharmaceutical community. CSBio has not raised any funding yet. The company has 64 active competitors, including 8 funded and 8 that have exited. Its top competitors include companies like Enzene, Shaanxi Micot Technology and PolyPeptide.

Company Details

Peptide synthesizers, DNA synthesizers, and peptide manufacturing for the pharmaceutical community. The company specializes in providing high-quality custom peptides, cGMP peptides, and automated peptide synthesizers. It serves the global pharmaceutical community with its peptide products and instrumentation found in production laboratories and pharmaceutical companies worldwide. The company offers a comprehensive portfolio of instruments, including peptide synthesizers and DNA synthesizers, alongside peptides from non-clinical to commercial scale. Services include cGMP peptides, peptide APIs, non-clinical peptides, and peptide resins and amino acids. The company is a leading instrumentation and peptide manufacturing company, providing best-in-class products and services.

Website: www.csbio.com/
Social
Email ID: *****@csbio.com
Phone Number: +1 **********
Registered Address: Menlo Park, California

Key Metrics

Founded Year

1993

Location

Menlo Park, United States

Stage

Unfunded

Ranked

18^th among 64 active competitors

Employee Count

59 as on Dec 31, 2022

Similar Companies

Enzene & 71 more

View CSBio's full profile

CSBio is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
CS PARK COMPANY LIMITED CIN: 0175560000042 , Thailand, Active	Feb 09, 2017	$23.3M (As on Dec 31, 2023)	-
C S Bio Co. CIN: 943009618 , United States, Active	Dec 31, 1999	-	59 (As on Dec 31, 2022)	-

CSBio has not raised any funding rounds yet.

CSBio's employee count trend

CSBio has 59 employees as of Dec 22. The total employee count is the same as what it was in Dec 21. Here is CSBio's employee count trend over the years:

Uncover CSBio's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of CSBio include Enzene, Shaanxi Micot Technology and PolyPeptide. Here is the list of Top 10 competitors of CSBio, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Enzene 2015, Pune (India), Series C	Company specializing in development of Biosimilars	$50M	F-Prime Capital, Eight Roads Ventures & 1 others	52/100
2nd	Shaanxi Micot Technology 2007, China, Series B	Provider of drug research and development services focused on cardiovascular and metabolic diseases	$72.2M	NLVC, Tasly & 2 others	46/100
3rd	PolyPeptide 1952, Baar (Switzerland), Public	CMO manufacturing proprietary,GMP grade and non-GMP-grade peptides	-	-	44/100
4th	Custom Peptide Synthesis 2011, Mumbai (India), Unfunded	Manufacturer of peptides and other finished formulations, & APIs	-	-	40/100
5th	Hybio Pharmaceutical 1998, Shenzhen (China), Public	Developer and manufacturer of polypeptide drugs and APis	$15M	Shenzhen Capital Group, SAIF Partners & 1 others	40/100
6th	AmbioPharm 2006, North Augusta (United States), Series B	Peptide manufacturing and development services, setting a new standard worldwide	$24M	The Carlyle Group, MVM	39/100
7th	USV Peptides 2011, Mumbai (India), Unfunded	CDMO offering custom peptide, GMP peptide and cosmetic peptide synthesis services	-	-	34/100
8th	JPT Peptide 2004, Berlin (Germany), Acquired	Peptide based CRO offering proteomics, biomarker and drug discovery services	-	-	32/100
9th	Ocelot Bio 2020, San Diego (United States), Deadpooled	CDMO focused on manufacturing of peptides	$36M	Vivo Capital, RA Capital Management & 1 others	32/100
10th	vivitide 1983, Gardner (United States), Acquired	Provider of drug development services for neoantigen peptide and antibody services	-	Ampersand Capital	31/100
18th	CSBio 1993, Menlo Park (United States), Unfunded	Peptide synthesizers, DNA synthesizers, and peptide manufacturing for the pharmaceutical community	-	-	28/100